A very high tumor mutational burden (TMB) is associated with improved efficacy of PD-(L)1 inhibition across different PD-L1 expression subgroups and a distinct immunophenotype in NSCLC.

被引：0
|
作者：
Ricciuti, Biagio [1 ]
Arbour, Kathryn C. [2 ]
Mahadevan, Navin R. [3 ]
Alessi, Joao V. [1 ]
Lindsay, James [1 ]
Umeton, Renato [1 ]
Sinha, Rileen [1 ]
Hoojghan, Amir [1 ]
Vokes, Natalie [1 ]
Recondo, Gonzalo [1 ]
Lamberti, Giuseppe [1 ]
Polio, Andrew [1 ]
Rizvi, Hira [2 ]
Leonardi, Giulia [1 ]
Plodkowski, Andrew J. [2 ]
Felt, Kristen [1 ]
Sharma, Bijaya [1 ]
Tolstorukov, Michael Y. [1 ]
Janne, Pasi A. [1 ]
Van Allen, Eliezer M. [1 ]
Sholl, Lynette M. [3 ]
Rodig, Scott J. [3 ]
Hellmann, Matthew D. [2 ]
Awad, Mark M. [1 ]
机构：
[1] Dana Farber Canc Inst, Boston, MA 02115 USA
[2] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA
[3] Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA
来源：
CANCER RESEARCH | 2021年 / 81卷 / 13期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
490
引用
收藏
页数：2
相关论文
共 50 条
  • [21] PD-L1 Expression is Related to Tumor Staging in NSCLC
    Wang, Hangjun
    Agulnik, Jason
    Kasymjanova, Goulnar
    Wang, Anna Y.
    Cohen, Victor
    Small, David
    Pepe, Carmela
    Sakr, Lama
    Fiset, Pierre O.
    Auger, Manon
    Camilleri-Broet, Sophie
    Alameldin, Mona
    Chong, George
    van Kempen, Leon
    Spatz, Alan
    LABORATORY INVESTIGATION, 2018, 98 : 755 - 755
  • [22] Association of a very high tumor mutational load with increased CD8+and PD-1+T-cell infiltration and improved clinical outcomes to PD-(L)1 blockade across different PD-L1 expression levels in non-small cell lung cancer.
    Ricciuti, Biagio
    Arbour, Kathryn Cecilia
    Alessi, Joao Victor Machado
    Mahadevan, Navin
    Lindsay, James
    Sinha, Rileen
    Vokes, Natalie I.
    Recondo, Gonzalo
    Lamberti, Giuseppe
    Rizvi, Hira
    Leonardi, Giulia Costanza
    Plodkowski, Andrew J.
    Felt, Kristen
    Tolstorukov, Michael
    Janne, Pasi A.
    Van Allen, Eliezer Mendel
    Sholl, Lynette M.
    Rodig, Scott J.
    Hellmann, Matthew D.
    Awad, Mark M.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [23] Distinct contribution of PD-L1 suppression by spatial expression of PD-L1 on tumor and non-tumor cells
    Xiaoqing Zhang
    Chen Cheng
    Jiyan Hou
    Xinyue Qi
    Xin Wang
    Ping Han
    Xuanming Yang
    Cellular & Molecular Immunology, 2019, 16 : 392 - 400
  • [24] Distinct contribution of PD-L1 suppression by spatial expression of PD-L1 on tumor and non-tumor cells
    Zhang, Xiaoqing
    Cheng, Chen
    Hou, Jiyan
    Qi, Xinyue
    Wang, Xin
    Han, Ping
    Yang, Xuanming
    CELLULAR & MOLECULAR IMMUNOLOGY, 2019, 16 (04) : 392 - 400
  • [25] Efficacy of Cabozantinib and Nivolumab in Treating Hepatocellular Carcinoma with RET Amplification, High Tumor Mutational Burden, and PD-L1 Expression
    Yang, Xiaobo
    Shi, Junping
    Chen, Xiaoqian
    Jiang, Yan
    Zhao, Haitao
    ONCOLOGIST, 2020, 25 (06): : 470 - 474
  • [26] Efficacy of anti-PD-1 antibodies in NSCLC patients with anEGFRmutation and high PD-L1 expression
    Masuda, Ken
    Horinouchi, Hidehito
    Tanaka, Midori
    Higashiyama, Ryoko
    Shinno, Yuki
    Sato, Jun
    Matsumoto, Yuji
    Okuma, Yusuke
    Yoshida, Tatsuya
    Goto, Yasushi
    Yamamoto, Noboru
    Ohe, Yuichiro
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2021, 147 (01) : 245 - 251
  • [27] The genomic landscape of immune-related genes and its correlations with TMB and PD-L1 expression in Chinese NSCLC.
    Zheng, Linxin
    Li, Weifeng
    Xie, Wenzhuan
    Huang, Mengli
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [28] PD-L1, Tumor Mutational Burden (TMB) and Intracranial Outcomes in Patients with Non -Small Cell Lung Cancer (NSCLC) and Brain Metastases
    Adib, E.
    Nassar, A. H.
    Kwiatkowski, D. J.
    Aizer, A. A.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2024, 120 (02): : E213 - E213
  • [29] Determination of PD-L1 Expression in Circulating Tumor Cells of NSCLC Patients and Correlation with Response to PD-1/PD-L1 Inhibitors
    Janning, Melanie
    Kobus, Franca
    Babayan, Anna
    Wikman, Harriet
    Velthaus, Janna-Lisa
    Bergmann, Sonja
    Schatz, Stefanie
    Falk, Markus
    Berger, Lars-Arne
    Boettcher, Lisa-Marie
    Paesler, Sarina
    Gorges, Tobias M.
    O'Flaherty, Linda
    Hille, Claudia
    Joosse, Simon A.
    Simon, Ronald
    Tiemann, Markus
    Bokemeyer, Carsten
    Reck, Martin
    Riethdorf, Sabine
    Pantel, Klaus
    Loges, Sonja
    CANCERS, 2019, 11 (06):
  • [30] Multiplex immunohistochemistry/immunofluorescence is superior to tumor mutational burden and PD-L1 immunohistochemistry for predicting response to anti-PD-1/PD-L1 immunotherapy
    Hu, Weixian
    THORACIC CANCER, 2020, 11 (01) : 3 - 5
12345